quinacrine has been researched along with Coronary Heart Disease in 10 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In quinacrine-treated animals left ventricular phospholipids and CK also fell during the first hours post-occlusion; however, 24 and 48 h after the occlusion they were significantly higher than in controls (phospholipids: 0." | 5.27 | [Limitation of the area of necrosis induced by quinacrine after coronary occlusion in the dog]. ( Ambrosio, G; Bigazzi, MC; Brigante, F; Chiariello, M; Focaccio, A; Migliaccio, C; Tritto, I, 1985) |
| " In the present study we sought to assess whether administration of the phospholipase inhibitor quinacrine would reduce the extent of myocardial necrosis after coronary artery occlusion." | 3.68 | Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion. ( Ambrosio, G; Cappelli-Bigazzi, M; Chiariello, M; Golino, P; Nevola, E; Perrone-Filardi, P; Tritto, I, 1990) |
| "In quinacrine-treated animals left ventricular phospholipids and CK also fell during the first hours post-occlusion; however, 24 and 48 h after the occlusion they were significantly higher than in controls (phospholipids: 0." | 1.27 | [Limitation of the area of necrosis induced by quinacrine after coronary occlusion in the dog]. ( Ambrosio, G; Bigazzi, MC; Brigante, F; Chiariello, M; Focaccio, A; Migliaccio, C; Tritto, I, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (50.00) | 18.7374 |
| 1990's | 5 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| VARMA, DR | 1 |
| MELVILLE, KI | 1 |
| Sargent, CA | 1 |
| Vesterqvist, O | 1 |
| McCullough, JR | 1 |
| Ogletree, ML | 1 |
| Grover, GJ | 1 |
| Armstrong, SC | 1 |
| Ganote, CE | 1 |
| Engels, W | 1 |
| Van Bilsen, M | 2 |
| De Groot, MJ | 1 |
| Lemmens, PJ | 1 |
| Willemsen, PH | 2 |
| Reneman, RS | 2 |
| Van der Vusse, GJ | 2 |
| Chiariello, M | 2 |
| Ambrosio, G | 2 |
| Cappelli-Bigazzi, M | 1 |
| Perrone-Filardi, P | 1 |
| Tritto, I | 2 |
| Nevola, E | 1 |
| Golino, P | 1 |
| Coumans, WA | 1 |
| Roemen, TH | 1 |
| Otani, H | 2 |
| Prasad, MR | 1 |
| Jones, RM | 1 |
| Das, DK | 2 |
| Jones, RL | 1 |
| Miller, JC | 1 |
| Hagler, HK | 1 |
| Chien, KR | 1 |
| Willerson, JT | 1 |
| Buja, LM | 1 |
| Engelman, RM | 1 |
| Rousou, JA | 1 |
| Breyer, RH | 1 |
| Lemeshow, S | 1 |
| Bigazzi, MC | 1 |
| Focaccio, A | 1 |
| Brigante, F | 1 |
| Migliaccio, C | 1 |
10 other studies available for quinacrine and Coronary Heart Disease
| Article | Year |
|---|---|
Ventricular fibrillation induced by coronary occlusion during hypothermia in dogs and the effects of quinidine, quinacrine, and oxytocin.
Topics: Animals; Coronary Disease; Coronary Occlusion; Dogs; Hypothermia; Hypothermia, Induced; Oxytocin; Qu | 1963 |
Effect of the phospholipase A2 inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 1992 |
Effects of the phospholipase inhibitor mepacrine on injury in ischemic and metabolically inhibited adult isolated myocytes.
Topics: Animals; Calcium; Cell Separation; Cell Survival; Coronary Disease; Glycolysis; Iodoacetates; Iodoac | 1991 |
Ischemia and reperfusion induced formation of eicosanoids in isolated rat hearts.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Coronary Disease; Eicosanoids; Fatty Acids; Hemodynami | 1990 |
Reduction in infarct size by the phospholipase inhibitor quinacrine in dogs with coronary artery occlusion.
Topics: Animals; Coronary Disease; Dogs; Hemodynamics; Myocardial Infarction; Myocardium; Necrosis; Phosphol | 1990 |
Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion.
Topics: Animals; Arrhythmias, Cardiac; Coronary Disease; Fatty Acids; Heart; Hemodynamics; Male; Myocardial | 1990 |
Mechanism of membrane phospholipid degradation in ischemic-reperfused rat hearts.
Topics: Animals; Arachidonic Acid; Arachidonic Acids; Calcium; Coronary Disease; Fatty Acids, Nonesterified; | 1989 |
Association between inhibition of arachidonic acid release and prevention of calcium loading during ATP depletion in cultured rat cardiac myocytes.
Topics: Adenosine Triphosphate; Animals; Arachidonic Acid; Arachidonic Acids; Calcium; Cells, Cultured; Coro | 1989 |
Role of membrane phospholipids in myocardial injury induced by ischemia and reperfusion.
Topics: 1-Acylglycerophosphocholine O-Acyltransferase; Acylation; Adenosine Triphosphate; Animals; Coenzyme | 1986 |
[Limitation of the area of necrosis induced by quinacrine after coronary occlusion in the dog].
Topics: Animals; Constriction; Coronary Disease; Creatine Kinase; Dogs; Male; Myocardium; Necrosis; Phosphol | 1985 |